How the FDA Regulates AI in Medical Devices

Artificial intelligence is changing how clinicians interpret scans, monitor patients and identify health risks. Algorithms can support radiologists, predict deterioration in intensive care and help automate measurements that once required manual review. Because these tools can influence diagnosis and treatment, regulators treat many of them as medical devices rather than ordinary software.

The US Food and Drug Administration oversees these products through its existing medical device framework, adapting established pathways to account for machine learning, changing algorithms and cybersecurity risks. The level of scrutiny depends on the intended use, the potential harm and whether a product is similar to an already authorised device.

This matters in Australia as hospitals in Sydney, Melbourne and Brisbane assess AI tools for imaging, emergency care and administration. A product cleared in the United States still needs to meet Australian requirements before it can be supplied locally, usually through the Therapeutic Goods Administration and the Australian Register of Therapeutic Goods.

For health services, clinicians and patients, the central issue is trust. An AI system must be demonstrably accurate, explainable enough for safe use, protected against cyber threats and monitored after deployment.

What counts as an AI medical device

The FDA generally regulates software according to its medical purpose and risk, not simply the technology used to build it. A machine-learning program that analyses chest X-rays for suspected disease may be regulated, while a basic appointment reminder normally is not.

Software can qualify as Software as a Medical Device when it performs a medical function without being part of a physical device. Some AI applications are embedded in scanners, patient monitors or surgical systems, creating a connected product with both hardware and software controls.

The main approval pathways

Lower- and moderate-risk products may use the 510(k) pathway to show substantial equivalence to a legally marketed device. If no suitable comparison exists, a developer may seek De Novo classification. High-risk products generally require the more demanding Premarket Approval process, supported by clinical evidence.

The FDA examines intended use, performance testing, usability, benefits and foreseeable risks. Developers must define the patient population and clinical setting clearly, since a tool validated in a major Melbourne teaching hospital may not perform identically in a small regional clinic or a rural Queensland service.

Managing algorithm changes

Traditional medical devices are reviewed as relatively fixed products, but machine-learning systems can change through software updates, new training data or revised thresholds. The FDA has proposed predetermined change control plans that allow manufacturers to describe expected future modifications in advance.

These plans can identify what will change, how the change will be tested and when a new submission may be needed. This approach aims to support useful updates without forcing manufacturers to restart the entire approval process for every controlled improvement.

Evidence, bias and clinical performance

Regulators expect evidence that an AI model performs safely for its intended users and patients. Testing should examine false positives, false negatives, reliability and performance across relevant ages, sexes, ethnic backgrounds and disease patterns.

Bias is a significant concern because training data may reflect one hospital, one country or one demographic group. Australian buyers should check whether imported systems have been evaluated on local data, including Aboriginal and Torres Strait Islander populations where relevant, rather than relying only on overseas results.

Cybersecurity and patient privacy

AI devices can create new attack surfaces because they may connect to hospital networks, cloud platforms and electronic health records. FDA expectations include secure design, vulnerability management, access controls, software updates and plans for responding to incidents.

Australian organisations must also consider the Privacy Act and health information obligations, especially when systems process identifiable records or send data offshore. A hospital using an AI service alongside My Health Record workflows needs clear rules for consent, retention, access and audit trails.

Oversight after market entry

Approval is not the end of regulatory responsibility. Manufacturers must monitor complaints, adverse events, unexpected outputs and cybersecurity weaknesses. In the United States, reporting and quality-system duties can apply when a device causes or contributes to serious harm.

The TGA follows a comparable risk-based approach for software and AI-enabled products, applying the Therapeutic Goods Act and relevant Essential Principles. Australian sponsors may need to include a product on the ARTG, while public hospitals also assess procurement, clinical governance and compatibility with Medicare-funded care.

What healthcare organisations should examine

A procurement team should ask what the algorithm does, who is accountable for its output and whether clinicians can safely override it. It should review validation data, update procedures, vendor support, downtime plans and the effect of errors on real patients.

Clear documentation is equally important. Organisations can use internal governance policies alongside their website terms when publishing information about digital health products, while keeping patient-facing explanations separate, plain and accessible.

AI can improve access to specialist support for communities in Western Australia, the Northern Territory and other regions where clinicians may be scarce. It should strengthen professional judgement rather than quietly replace it, especially when data quality, connectivity or local disease patterns differ from the conditions used during development.

Staying informed about FDA decisions, TGA guidance and real-world safety reports helps Australian readers and health leaders judge new medical technology more carefully. Follow developing health and technology coverage on CAPosts.com to track how regulation shapes the next generation of clinical tools.